Tumor Biology

Volume

43, 1 issue

Latest issue

43:1 online 19 May 2021

ISSN online

1423-0380
Open Access
Online Only

Aims & Scope

Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. It covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression.

Specific topics of interest include, but are not limited to:

• Pathway analyses
• Non-coding RNAs
• Circulating tumor cells
• Liquid biopsies
• Exosomes
• Epigenetics
• Cancer stem cells
• Tumor immunology and immunotherapy
• Tumor microenvironment
• Targeted therapies
• Therapy resistance
• Cancer genetics
• Cancer risk screening.

Studies in other areas of basic, clinical, and translational cancer research are also considered in order to promote connections and discoveries across different disciplines.

The journal publishes original articles, reviews, commentaries, and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication.

Tumor Biology is the official journal of the International Society of Oncology and BioMarkers (ISOBM).

Editorial Board

Editor-in-Chief

Magdalena Chechlinska, PhD, Dr Habil
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw
Poland
E-mail: TumorBiology.Editor@pib-nio.pl

Associate Editors

Changyan Chen
Northeastern University, Boston
USA

Stefan Holdenrieder
University of Bonn, Bonn
Germany

Magdalena Kowalewska
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
Poland

Salvatore Piscuoglio
University Hospital Basel, Basel
Switzerland

Marta Sanchez-Carbayo
University of the Basque Country, Leioa
Spain

Editorial Board

Vivian Barak
Hadassah Medical Center, Jerusalem
Israel

Javier Castresana
University of Navarra, Pamplona
Spain

Caroline Chapman
University of Nottingham, Nottingham
United Kingdom

Chi Hin Cho
The Chinese University of Hong Kong, Hong Kong
China

Jose Luis Costa
University of Porto, Porto
Portugal

Elefterious Diamandis
Mount Sinai Hospital, Toronto
Canada

Joe Duffy
University College Dublin, Dublin
Ireland

Sten Hammarström
Umeå Universitet, Umeå
Sweden

Kohzoh Imai
The University of Tokyo, Tokyo
Japan

Chien-Feng (Angelo) Li
Chi Mei Medical Center
Taiwan

Leendert H. J. Looijenga
Erasmus MC Cancer Institute, Rotterdam
The Netherlands

Andrea Nicolini
University of Pisa, Pisa
Italy

Barbara Pedley
University College London
London, United Kingdom

Johanna (Hanny) M.A. Pijnenborg
Radboud University Medical Center, Nijmegen
The Netherlands

Ulf Hakan Stenman
University of Helsinki, Helsinki
Finland

Iwona Wlodarska
Katholieke Universiteit Leuven, Leuven
Belgium

Author Guidelines

Tumor Biology, launched in 1980 (formerly published as Oncodevelopmental Biology and Medicine), is a peer reviewed, open access journal publishing experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. 

The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous single-blind peer review and are selected on the basis of whether the research is sound and deserves publication.

SUBMISSION OF MANUSCRIPT

By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

Authors are requested to submit their manuscript electronically to the journal’s editorial management system. The manuscript should be uploaded as one file with tables and figures included. Please use the journal's manuscript template.

The journal does not accept submissions from authors using nondescript, anonymous, email addresses (e.g. yahoo.com, gmail.com, 163.com, rediffmail.com, sina.com, 126.com, hotmail.com, etc.). Institutional email addresses are highly preferred.

Required files

  • Cover letter
  • Main document (with figures and tables)
  • Source files

A .pdf file of the article is required along with the source files of the text, such as MS Word or LaTeX. If using LaTeX, please use the standard article.sty as a style file. LaTeX packages should be compiled into .zip or .rar files.

Open access fee
Papers submitted to Tumor Biology that are accepted for publication will be subject to an open access fee. The current open access fee is US$1500 / €1250 (excl. VAT if applicable) to publish under the CC BY-NC 4.0 license. To publish under a CC BY 4.0 license, as mandated by certain funding agencies, the fee is US$2000 / €1675 (excl. VAT if applicable). An order form will be provided along with the PDF proof.

Waiver requests can be considered for corresponding authors from low-income countries listed in the Research4Life project.

Check to see if you may be eligible to a discount or waiver due to the open access institutional deals.

PREPARATION OF MANUSCRIPTS

Cover Letter
The cover letter is important. To help the Editors in their preliminary evaluation, please indicate why you think the paper is suitable for publication. For original research articles, authors should also use this space to indicate the novelty of their work.

Article Types
Original article
This form of manuscript presents new clinical and experimental findings. Articles should be 2,000–3,000 words long. Authors should therefore consider what data and analyses may be appropriate for supplemental information. There is no limit to the number of references. The article should be structured appropriately, and abstracts should follow the following format: Background, Objective, Methods, Results and Conclusions.

Review article
Tumor Biology accepts comprehensive reviews on topics related to experimental and clinical cancer research, and related topics. Reviews must contain no more than 5,000 words. There is no limit to Figures or references, but authors are advised that the Editorial Board will not accept poorly-focused reviews.

Commentaries
Are opinion pieces that initiate or focus discussion on current and emerging topics related to tumor biology. This article type should propose a valid argument or support a point of view with strong evidence with in limit of 2,000 words.

Organization of the Paper and Style of Presentation
Manuscripts must be written in English. Authors whose native language is not English are recommended to seek the advice of a native English speaker, if possible, before submitting their manuscripts. Peerwith offers a language and copyediting service to all scientists who want to publish their manuscript in scientific peer-reviewed periodicals and books.

Manuscripts should be prepared with wide margins and double spacing throughout, including the abstract, footnotes and references. Every page of the manuscript, including the title page, references, tables, etc., should be numbered. However, in the text no reference should be made to page numbers; if necessary, one may refer to sections. Try to avoid the excessive use of italics and bold face.
Manuscripts should be organized in the following order:

  • Title page
  • Text body (divided by subheadings)
  • Acknowledgements
  • Author contributions
  • References
  • Tables
  • Figure captions
  • Figures

Headings and subheadings should be numbered and typed on a separate line, without indentation.

SI units should be used, i.e., the units based on the metre, kilogramme, second, etc.

Title Page
The title page should provide the following information:

  • Title (should be clear, descriptive and not too long)
  • Name(s) of author(s) without abbreviation; please indicate who is the corresponding author. Note that no authors will be added or removed post submission, unless the journal editor and all co-authors are informed and are in agreement to this change.
  • Full affiliation(s)
  • Present address of author(s), if different from affiliation
  • Complete address of the corresponding author, including tel. no., fax no., e-mail address and ORCID ID
  • Abstract
  • Keywords.

Abstract
The abstract should be clear, descriptive, self-explanatory and not longer than 200 words, it should also be suitable for publication in abstracting services.
The abstract for research papers should follow the “structured abstract” format. Section labels should be in bold uppercase letters followed by a colon, and each section will begin on a new line.
BACKGROUND:
OBJECTIVE:
METHODS:
RESULTS:
CONCLUSIONS:

Materials and Methods
Experimental subjects
When human subjects are used, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and written consent of each subject, and that the study conforms with the Code of Ethics of the World Medical Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964).

When experimental animals are used, the Materials and methods section must briefly but explicitly state measures which were taken to minimize pain or discomfort, e.g. type and dose of anaesthetic used. Experiments should be carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) or with the Guidelines laid down by the NIH in the US, available from the Office of Laboratory Animal Welfare, National Institutes of Health, Department of Health and Human Services, RKLI, Suite 360, MSC 7982, 6705 Rockledge Drive, Bethesda, MD 20892-7982, or online (http://grants.nih.gov/grants/olaw/olaw .htm#pol) regarding the care and use of animals for experimental procedures.

All studies using human or animal subjects should include an explicit statement in the Materials and Methods section identifying the review and approval committee for each study. Editors reserve the right to reject papers if there is doubt whether appropriate procedures have been used.

Acknowledgments
This section should contain all acknowledgments, including any funding source to the research.

Author Contributions
For every author, his or her contribution to the manuscript needs to be provided using the following categories:
CONCEPTION:
DATA CURATION:
ANALYSIS OF DATA:
PREPARATION OF THE MANUSCRIPT:
REVISION FOR IMPORTANT INTELLECTUAL CONTENT:
SUPERVISION:

Conflict of Interest
Tumor Biology requires authors to declare all conflicts of interest, financial or otherwise, independent of relevance to the particular manuscript. All authors must separately be named in the Conflict of interest statement. If an author has no conflict of interest to declare, include this section with the statement “(Name) has no conflict of interest to report”.

References

Authors are requested to use the Vancouver citation style. All publications cited in the text should be presented in a list of references at the end of the manuscript. List the references in the order in which they appear in the text. If an article has a DOI, this should be provided after the page number details. The number is added after the letters 'doi'. The following are examples of correct citations in the Vancouver citation style:

[1] Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002; 935(1-2): 40-6. doi: 10.1016/s0006-8993(02)02445-9
[2] Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
[3] Berkow R, Fletcher AJ, editors. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories; 1992.
[4] Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGrawHill; 2002. p. 93113.
[5] Canadian Cancer Society [homepage on the Internet]. Toronto: The Society; 2006 [updated 2006 May 12; cited 2006 Oct 17]. Available from: www.cancer.ca/.

Footnotes

Footnotes should only be used if absolutely essential. In most cases it is possible to incorporate the information in the text.

If used, they should be numbered in the text, indicated by superscript numbers and kept as short as possible.

Tables
Number as Table 1, Table 2 etc., and refer to all of them in the text.
Each table should be provided on a separate page of the manuscript. Tables should not be included in the text.
Each table should have a brief and self-explanatory title.
Column headings should be brief, but sufficiently explanatory. Standard abbreviations of units of measurement should be added between parentheses.
Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.
Any explanations essential to the understanding of the table should be given in footnotes at the bottom of the table.

Figures
Number figures as Fig. 1, Fig. 2, etc. and refer to all of them in the text.

Each figure should be provided on a separate sheet. Figures should not be included in the text.

For the file formats of the figures please take the following into account:
- Line art should be have a minimum resolution of 600 dpi, save as EPS or TIFF
- Grayscales (incl. photos) should have a minimum resolution of 300 dpi (no lettering), or 500 dpi (when there is lettering); save as tiff
- Do not save figures as JPEG, this format may lose information in the process
- Do not use figures taken from the Internet, the resolution will be too low
- Figures should be designed with the format of the page of the journal in mind. They should be of such a size as to allow a reduction of 50%.

On maps and other figures where a scale is needed, use bar scales rather than numerical ones, i.e., do not use scales of the type 1:10,000. This avoids problems if the figures need to be reduced.

Each figure should have a self-explanatory caption. The captions to all figures should be typed on a separate sheet of the manuscript.

Photographs are only acceptable if they have good contrast and intensity.

COPYRIGHT

Copyright of Your Article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Quoting from Other Publications
An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.

PROOFS

The corresponding author will receive a PDF proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.

PURCHASES

Complimentary Copy
The corresponding author of a contribution to this journal will receive a pdf copy of their published article on release.

How to Order Reprints, a PDF File, Journals, or IOS Press Books
If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press, Fax: +31 20 687 0019. Email: editorial@iospress.nl.

An author is entitled to 25% discount on IOS Press books. See Author's discount (25%) on all IOS Press book publications.

KUDOS

Authors of published articles (non-prepress, final articles) will be contacted by Kudos. Kudos is a service that helps researchers maximize the impact and visibility of their research. It allows authors to enrich their articles with lay metadata, add links to related materials and promote their articles through the Kudos system to a wider public. Authors will receive no more than three emails: one invitation and a maximum of two reminders to register for the service and link the published article to their profile. Using and registering for Kudos remains entirely optional. For more information, please have a look at our authors section.

HOW TO PROMOTE YOUR WORK

Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.

Abstracted/Indexed in

Directory of Open Access Journals (DOAJ)
MEDLINE
ProQuest
PubMed
Scopus
 

Extra

New from 2021: Tumor Biology is published by IOS Press as of January 1, 2021 onwards. Articles will be available on our content platform by the end of March 2021. The journal is published in association with the International Society of Oncology and BioMarkers.

Recent back issues: All content in Volumes 39 to 42 can be accessed via the Sage journal platform here.

Keep updated: If you are interested to be informed about the journal, please sign up for news here. You can view the latest mailing here.

Peer Review

Tumor Biology Peer Review Policy

Tumor Biology is a peer-reviewed journal. Articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors.

All submitted manuscripts are subjected to initial appraisal by the Editor-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be that the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.

Papers deemed suitable to be reviewed will be assigned to a handling editor. The handling editor will then invite reviewers to comment on the work. Editors and reviewers are asked to excuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s).

As a standard policy, decisions are based on two reviews. The Editor-in-Chief strives to ensure a typical turnaround time of 3 months.

Reviewers are asked to judge a paper on at least:

  • Significance to field
  • Relevance to journal
  • Methodology
  • Data analysis
  • Literature review
  • Writing style/clarity

Based on the received reviews the handling editor will propose to the Editor-in-Chief a recommendation:

  1. Accept
  2. Minor revisions required
  3. Major revisions required
  4. Reject

They mean the following:

  1. The manuscript is suitable for publication, thus no further reviews are requested.
  2. The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors have been addressed satisfactorily. The revised manuscript will be examined by the Editor-in-Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
  3. The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
  4. The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.

Authors are notified by the Editor-in-Chief, whose decision is final.